The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
Abstract
PURPOSE: To evaluate the antitumor activity of 96-hour paclitaxel and daily oral estramustine phosphate (EMP) in patients with metastatic hormone-refractory prostate cancer (HRPC). PATIENTS AND METHODS: Thirty-four patients with adenocarcinoma of the prostate that progressed after one or more hormonal therapies and a trial of antiandrogen withdrawal were enrolled onto this phase II trial. Patients received paclitaxel 120 mg/m2 by 96-hour intravenous (i.v.) infusion on days 1 through 4 of each 21-day cycle, together with daily oral EMP 600 mg/m2/d, continuously. RESULTS: Four of nine patients with measurable disease had objective responses (one complete response [CR] and three partial responses [PRs]) in liver (two patients) or nodes (two patients) of 2, 6, 8, and 20 months' duration. Of 25 assessable patients with metastases limited to bone, 14 had a > or = 50% decline in pretreatment prostate-specific antigen (PSA) level sustained for at least 6 weeks and seven had a > or = 80% decline. Overall, 17 of 32 patients (53.1%) with elevated pretreatment PSA levels had a > or = 50% decline of PSA and nine (28.1%) had a > or = 80% decrease. The main toxicities (> or = grade 2) were nausea, fluid retention, and fatigue, which occurred in 33%, 33%, and 24.2% of patients. Median time to progression, based on increasing PSA level and other clinical criteria, was 22.5 weeks. The estimated median overall survival time is 69 weeks. CONCLUSION: The combination of EMP and 96-hour paclitaxel is an active regimen for patients with HRPC. These results further support the therapeutic strategy of combining agents that impair microtubule function by complementary mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
Scher, H. I., & Kelly, W. K. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1566 · Cited by 405
Microtubule dynamics in vitro are regulated by the tubulin isotype composition.
Panda, D., Miller, H. P., Banerjee, A., Ludueña, R. F., & Wilson, L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11358 · Cited by 374
A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.
Eisenberger, M. A., Simon, R., O'Dwyer, P. J., Wittes, R. E., & Friedman, M. A. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.6.827 · Cited by 267
Hudes, G. R., Greenberg, R., Krigel, R. L., Fox, S., Scher, R., Litwin, S., Watts, P., Speicher, L., Tew, K., & Comis, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.11.1754 · Cited by 256
Self-citationPienta, K. J., Redman, B., Hussain, M., Cummings, G., Esper, P. S., Appel, C., & Flaherty, L. E. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2005 · Cited by 220
Wilson, W. H., Berg, S. L., Bryant, G., Wittes, R. E., Bates, S., Fojo, A., Steinberg, S. M., Goldspiel, B. R., Herdt, J., & O'Shaughnessy, J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1621 · Cited by 216
Seidman, A. D., Scher, H. I., Petrylak, D., Dershaw, D. D., & Curley, T. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37426-8 · Cited by 200
Roth, B. J., Loehrer, P. J., Yeap, B. Y., Wilding, G., Kasimis, B. S., & McLeod, D. G. (1993) · Cancer · doi:10.1002/1097-0142(19931015)72:8<2457::aid-cncr2820720825>3.0.co;2-z · Cited by 168
Estramustine depolymerizes microtubules by binding to tubulin.
Dahllöf, B., Billström, A., Cabral, F., & Hartley‐Asp, B. (1993) · PubMed · Cited by 148
Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines.
Speicher, L. A., Barone, L. R., & Tew, K. D. (1992) · PubMed · Cited by 138
Sella, A., Kilbourn, R. G., Amato, R. J., Bui, C., Zukiwski, A. A., Ellerhorst, J. A., & Logothetis, C. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.4.683 · Cited by 121
Ranganathan, S., Dexter, D., Benetatos, C. A., Chapman, A. E., Tew, K. D., & Hudes, G. R. (1996) · PubMed · Cited by 113
Self-citationStearns, M. E., Wang, M., Tew, K. D., & Binder, L. I. (1988) · The Journal of Cell Biology · doi:10.1083/jcb.107.6.2647 · Cited by 76
Interaction of estramustine phosphate with microtubule‐associated proteins
Wallin, M., Deinum, J., & Fridén, B. (1985) · FEBS Letters · doi:10.1016/0014-5793(85)80536-6 · Cited by 71
Kinney, A. Y., Vernon, S. W., Frankowski, R. F., Weber, D. M., Bitsura, J. M., & Vogel, V. G. (1995) · Cancer · doi:10.1002/1097-0142(19950701)76:1<96::aid-cncr2820760114>3.0.co;2-e · Cited by 68
Small, E. J., Srinivas, S., Egan, B. C., McMillan, A., & Rearden, T. P. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1617 · Cited by 48
Burns, R. G. (1990) · Cell Motility and the Cytoskeleton · doi:10.1002/cm.970170304 · Cited by 13
Cited by
A history of prostate cancer treatment.
Denmeade, S. R., & Isaacs, J. T. (2002) · Nature reviews. Cancer · doi:10.1038/nrc801 · Cited by 591
Carducci, M. A., Padley, R. J., Breul, J., Vogelzang, N. J., Zonnenberg, B. A., Daliani, D. D., Schulman, C. C., Nabulsi, A. A., Humerickhouse, R. A., Weinberg, M. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.176 · Cited by 371
Savarese, D. M., Halabi, S., Hars, V., Akerley, W. L., Taplin, M.-E., Godley, P. A., Hussain, A., Small, E. J., & Vogelzang, N. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2509 · Cited by 323
How Do Microtubule-Targeted Drugs Work? An Overview
Jordan, M., & Kamath, K. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907783220417 · Cited by 270
Vaishampayan, U., Fontana, J., Du, W., & Hussain, M. (2002) · Urology · doi:10.1016/s0090-4295(02)01990-8 · Cited by 32
Metadata
- Authors
- Hudes, G. R., Nathan, F., Khater, C., Haas, N., Cornfield, M., Giantonio, B., Greenberg, R., Gomella, L., Litwin, S., Ross, E., Roethke, S., & McAleer, C.
- Venue
- Journal of Clinical Oncology
- Published
- 1997-09
- Volume
- 15
- Issue
- 9
- Pages
- 3156-3163
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1816774827
- Cited by
- 272
- References
- 18
- FWCI
- 20.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.